Key result
Ocrelizumab infusion may trigger severe but reversible LVSD in patients with multiple sclerosis.
Why the study?
Does ocrelizumab infusion cause severe left ventricular systolic dysfunction or cardiogenic shock in patients with relapsing-remitting multiple sclerosis?
Does ocrelizumab infusion cause severe left ventricular systolic dysfunction or cardiogenic shock in patients with relapsing-remitting multiple sclerosis?
Ocrelizumab may rarely cause severe, reversible left ventricular systolic dysfunction, highlighting the need for vigilance regarding cardiotoxicity in patients receiving this therapy.
Alerts to possible ocrelizumab cardiotoxicity in MS; single case leaves causality and monitoring needs open.
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and worsened over 10 days. A thorough diagnostic evaluation, including blood tests, coronary artery angiography, cardiac magnetic resonance imaging, and endomyocardial biopsy excluded ischemic or infectious causes of myocardial damage. Although cardiac complications have not previously been reported with ocrelizumab, this case suggests the drug may rarely cause reversible severe cardiac dysfunction and highlights the importance of vigilance for cardiotoxicity in people with multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Napoli et al. (2025) studied this question. Ocrelizumab infusion may lead to reversible severe left ventricular systolic dysfunction in patients with multiple sclerosis, as seen in a 42-year-old man without prior cardiac issues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: